title: Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension.
abstract: The efficacy and safety of doxazosin (DOX) for the treatment of hypertension was investigated. A multicenter, double-blind, placebo-controlled, parallel design was employed. A 4-week placebo runin period was followed by a 9-week double-blind period during which patients were randomly assigned to placebo or 2, 4, or 8 mg doxazosin. Blood pressures (BP) and heart rates (HR) were measured 24 hours postdose. The mean changes in standing BP (mmHg) were -6.2/-6.9 (2-mg regimen), -5.7/-5.8 (4-mg regimen), -8.5/-7.7 (8-mg regimen) for DOX patients and 0.7/-2.9 for placebo patients. The mean changes in supine BP (mmHg) were -3.2/-4.7 (2-mg regimen), -4.0/-5.1 (4-mg regimen), -4.6/-5.6 (8-mg regimen) for DOX patients and -0.5/-3.3 for placebo patients. There was no evidence of a dose-response relationship for DOX; however, DOX serum levels were linearly related to the dose. Responder rate for the combined DOX patients was 38% (32/84) and for the placebo patients 27% (8/30). HR (24 hours postdose) was not modified by DOX. Patients in the 8-mg regimen had a significantly higher gain in mean body weight (+ 1.3 +/- 0.3 kg; P less than 0.05) compared to the 2-mg regimen, 4-mg regimen, and placebo groups. Plasma norepinephrine was not significantly modified by DOX. DOX had a favorable effect on plasma lipids. DOX lowered LDL cholesterol (P less than 0.05), total cholesterol, and apoprotein B and increased HDL/(LDL + VLDL) ratio (0.05 less than or equal to P less than 0.1) compared to placebo. Dropout rate and treatment-related side effects were equally distributed among the DOX and placebo groups. No patients had the dose of medication reduced because of side effects. Three DOX patients were withdrawn because of postural dizziness.
authors.affiliation: Department of Pharmacology, University of North Carolina, Chapel Hill 27514.
authors.forename: L X
authors.initials: LX
authors.lastname: Cubeddu
authors.forename: J L
authors.initials: JL
authors.lastname: Pool
authors.forename: R
authors.initials: R
authors.lastname: Bloomfield
authors.forename: P E
authors.initials: PE
authors.lastname: Klotman
authors.forename: B I
authors.initials: BI
authors.lastname: Pickering
authors.forename: D G
authors.initials: DG
authors.lastname: Wombolt
authors.forename: E B
authors.initials: EB
authors.lastname: Nelson
authors.forename: A
authors.initials: A
authors.lastname: Halperin
mesh_terms: D001794:Blood Pressure / Q000187:drug effects*; D017292:Doxazosin; D005260:Female; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use
chemical_list: D008055:Lipids; D017292:Doxazosin; D009638:Norepinephrine; D011224:Prazosin